DXC-TECHNOLOGY
DXC Technology (NYSE: DXC), the world’s leading independent, end-to-end IT services company, today announced the opening of the DXC Innovation Centre in London for the company and its clients to develop and deliver high-impact digital solutions.
DXC’s London Innovation Centre is a collaborative environment that draws on the company’s global experience in digital transformation, leverages its rich industry knowledge and independent partner network, and creates an environment for the incubation of ideas, learning and development.
The London Innovation Centre adds to DXC’s digital network in the UK, which includes a Digital Transformation Centre in Newcastle that is already helping customers to transform and accelerate the creation of business value. As part of this network, DXC digital technologists and enterprise solution experts will work with customers and partners to modernize and integrate mainstream IT by deploying digital solutions at scale.
“Our Innovation Centre brings together innovative technologies, creative thinking and best practices to develop innovative solutions for clients in a rapidly changing digital era,” said Maruf Majed , vice president and general manager, DXC UK, Ireland, Israel, Middle East and Africa. “The Innovation Centre creates opportunities for our people, clients and partners to gain valuable practical experience with digital technology in real-life business applications.”
Local and Global Digital Ideation
The London Centre showcases emerging digital technologies such as machine learning, artificial intelligence, IoT, blockchain and robotics. There will be a focus on sectors including government, energy and utilities, healthcare and life sciences, travel and transport, insurance, financial services and manufacturing.
As part of DXC’s global network of digital experience centres, the London facility will draw from global teams of digital specialists who are working on digital journey mapping and the co-creation of leading-edge prototypes. The goal is to build enterprise-grade, secure and globally scalable solutions for rapid deployment in customer environments.
Development, Engagement and Experiential Opportunities
The Innovation Centre will create new learning and career development opportunities for DXC employees – including personal and organizational digital skills and capabilities – and will contribute to the wider technology and business communities in the UK.
Initial digital client engagements will focus on:
- Digital Account Opening – For customers interacting digitally with their banking providers, who have an obligation to their customers and are bound by government regulation, to ensure that interactions are carried out lawfully;
- Field Worker Effectiveness – Using the latest voice-controlled headsets and the ability to connect workers using digital workflows, tasks can be carried out efficiently and details uploaded into business systems;
- KPI Dashboard – Providing a C-level view of enterprise key performance indicators; and
- Smart Factory Concept – Increasing productivity through digital manufacturing technologies and IoT.
Representing a view from the DXC Partner Network, Peter Almond, PwC Alliance Director, said: “The launch of DXC’s London Innovation Centre provides PwC with a powerful extension to its own eco-system of customer experience centres and brings the ability to co-create innovative digital solutions that are rooted in the realities that come with deploying technology at scale across complex enterprise environments.”
DXC’s London Innovation Centre will also leverage research and frameworks that address the concepts of “Winning in the 21st Century Organisation” and “Developing the mindsets of 21st Century Humans” from Leading Edge Forum , an independent think tank.
About DXC Technology
As the world's leading independent, end-to-end IT services company, DXC Technology (NYSE: DXC) leads digital transformations for clients by modernizing and integrating their mainstream IT, and by deploying digital solutions at scale to produce better business outcomes. The company’s technology independence, global talent, and extensive partner network enable 6,000 private and public-sector clients in 70 countries to thrive on change. DXC is a recognized leader in corporate responsibility. For more information, visit dxc.technology and explore THRIVE , DXC’s digital destination for changemakers and innovators.
About Leading Edge Forum (LEF)
Leading Edge Forum is an independent think tank, committed to helping clients embrace opportunities created by disruption. With its global ecosystem of industry-leading practitioners, disruptors and innovators, LEF creates progressive research and next-practice advisory interventions that agitate clients to activate change and accelerate impact with their own organizations and customers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190618005104/en/
Contact:
Marketing & Communications Director, UKIIMEA Natasha Cowan T +44 20 3882 4422 ncenta2@dxc.com
Corporate Media Relations Donna Jenks +1-630-306-9989 donna.jenks@dxc.com
Investor Relations Jonathan Ford +1-703-245-9700 jonathan.ford@dxc.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom